{"prompt": "['Product: MK-3475', '120', 'Protocol/Amendment No.: 604-09', 'Trial documentation will be promptly and fully disclosed to the Sponsor by the investigator', 'upon request and also shall be made available at the trial site upon request for inspection,', 'copying, review and audit at reasonable times by representatives of the Sponsor or any', 'regulatory authorities. The investigator agrees to promptly take any reasonable steps that are', 'requested by the Sponsor as a result of an audit to cure deficiencies in the trial documentation', 'and worksheets/case report forms.', 'The investigator must maintain copies of all documentation and records relating to the', 'conduct of the trial in compliance with all applicable legal and regulatory requirements. This', 'documentation includes, but is not limited to, the protocol, worksheets/case report forms,', 'advertising for subject participation, adverse event reports, subject source data,', \"correspondence with regulatory authorities and IRBs/ERCs, consent forms, investigator's\", 'curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or', 'quality control procedures and laboratory director curriculum vitae. By signing this protocol,', 'the investigator agrees that documentation shall be retained until at least 2 years after the last', 'approval of a marketing application in an ICH region or until there are no pending or', 'contemplated marketing applications in an ICH region or until at least 2 years have elapsed', 'since the formal discontinuation of clinical development of the investigational product.', 'Because the clinical development and marketing application process is variable, it is', 'anticipated that the retention period can be up to 15 years or longer after protocol database', 'lock. The Sponsor will determine the minimum retention period and notify the investigator', 'when documents may be destroyed. The Sponsor will determine the minimum retention', 'period and upon request, will provide guidance to the investigator when documents no longer', 'need to be retained. The Sponsor also recognizes that documents may need to be retained for', 'a longer period if required by local regulatory requirements. All trial documents shall be', 'made available if required by relevant regulatory authorities. The investigator must consult', 'with and obtain written approval by the Sponsor prior to destroying trial and/or subject files.', \"ICH Good Clinical Practice guidelines recommend that the investigator inform the subject's\", \"primary physician about the subject's participation in the trial if the subject has a primary\", 'physician and if the subject agrees to the primary physician being informed.', 'The investigator will promptly inform the Sponsor of any regulatory authority inspection', 'conducted for this trial.', 'Persons debarred from conducting or working on clinical trials by any court or regulatory', \"authority will not be allowed to conduct or work on this Sponsor's trials. The investigator\", 'will immediately disclose in writing to the Sponsor if any person who is involved in', 'conducting the trial is debarred or if any proceeding for debarment is pending or, to the best', \"of the investigator's knowledge, threatened.\", 'In the event the Sponsor prematurely terminates a particular trial site, the Sponsor will', \"promptly notify that trial site's IRB/IEC.\", 'According to European legislation, a Sponsor must designate an overall coordinating', 'investigator for a multi-center trial (including multinational). When more than one trial site', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '121', 'Protocol/Amendment No.: 604-09', 'is open in an EU country, Merkk, as the Sponsor, will designate, per country, a national', 'principal coordinator (Protocol CI), responsible for coordinating the work of the principal', 'investigators at the different trial sites in that Member State, according to national', 'regulations. For a single-center trial, the Protocol CI is the principal investigator. In', 'addition, the Sponsor must designate a principal or coordinating investigator to review the', 'trial report that summarizes the trial results and confirm that, to the best of his/her', 'knowledge, the report accurately describes the conduct and results of the trial [Clinical Study', 'Report (CSR) CI]. The Sponsor may consider one or more factors in the selection of the', 'individual to serve as the Protocol CI and or CSR CI (e.g., availability of the Protocol/CSR', 'CI during the anticipated review process, thorough understanding of clinical trial methods,', 'appropriate enrollment of subject cohort, timely achievement of trial milestones). The', 'Protocol CI must be a participating trial investigator.', '10.4 Compliance with Trial Registration and Results Posting Requirements', 'Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007', 'and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor', 'of the trial is solely responsible for determining whether the trial and its results are subject to', 'the', 'requirements', 'for', 'submission', 'to', 'http://www.clinicaltrials.gov,', 'www.clinicaltrialsregister.eu or other local registries. Merkk, as Sponsor of this trial, will', 'review this protocol and submit the information necessary to fulfill these requirements.', 'Merk entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.', 'Information posted will allow subjects to identify potentially appropriate trials for their', 'disease conditions and pursue participation by calling a central contact number for further', 'information on appropriate trial locations and trial site contact information.', 'By signing this protocol, the investigator acknowledges that the statutory obligations under', 'FDAAA, the EMA clinical trials directive or other locally mandated registries are that of the', 'Sponsor and agrees not to submit any information about this trial or its results to those', 'registries.', '10.5 Quality Management System', 'By signing this protocol, the Sponsor agrees to be responsible for implementing and', 'maintaining a quality management system with written development procedures and', 'functional area standard operating procedures (SOPs) to ensure that trials are conducted and', 'data are generated, documented, and reported in compliance with the protocol, accepted', 'standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and', 'regulations relating to the conduct of the clinical trial.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}